总时间（秒）：26.28
问答时间（秒）：23.73

{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "PINK1",
                "Protein_Change": {
                    "ref": "Wildtype",
                    "alt": "",
                    "position": ""
                },
                "variant_string_id": "PINK1 WT"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "The paper clearly defines that mutations in PINK1 cause an autosomal recessive form of Parkinson’s disease (PD), PARK6. PINK1 is a mitochondrial Ser/Thr kinase, and the mutant PINK1 or PINK1 knock-down causes deficits in mitochondrial respiration and ATP synthesis, impaired proteasome function, and increased a-synclein aggregation.",
                    "judgment": "Yes",
                    "reasoning": "The paper provides explicit statements about the disease's molecular basis and how the PINK1 gene/protein functions within it."
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The paper uses in vitro cell culture systems to investigate the effects of mutant PINK1 or PINK1 knock-down on mitochondrial function, proteasome function, and a-synclein aggregation.",
                    "judgment": "Yes",
                    "reasoning": "The use of in vitro cell culture systems is a standard technique in the field for studying Parkinson's disease pathogenesis."
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_steps": [
                        {
                            "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                            "questions": [
                                {
                                    "question": "Were basic controls included for this assay? Specifically, were 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                    "answer": "Yes"
                                },
                                {
                                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                    "answer": "Not specified"
                                }
                            ]
                        },
                        {
                            "sub_step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                            "questions": []
                        },
                        {
                            "sub_step_name": "Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a)",
                            "questions": [
                                {
                                    "question": "Were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                    "answer": "Not specified"
                                }
                            ]
                        },
                        {
                            "sub_step_name": "Sub-step 4a: Statistical Analyses",
                            "questions": [
                                {
                                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                    "answer": "Not specified"
                                }
                            ]
                        },
                        {
                            "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                            "questions": [
                                {
                                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                    "answer": "Not specified"
                                }
                            ]
                        },
                        {
                            "sub_step_name": "Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient)",
                            "questions": []
                        }
                    ]
                }
            ],
            "functional_evidence_strength": "Max PS3_supporting / Max BS3_supporting"
        },
        {
            "variant_id": {
                "Gene": "PINK1",
                "Protein_Change": {
                    "ref": "Mutant PINK1",
                    "alt": "",
                    "position": ""
                },
                "variant_string_id": "PINK1 Mut"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "The paper clearly defines that mutations in PINK1 cause an autosomal recessive form of Parkinson’s disease (PD), PARK6. PINK1 is a mitochondrial Ser/Thr kinase, and the mutant PINK1 or PINK1 knock-down causes deficits in mitochondrial respiration and ATP synthesis, impaired proteasome function, and increased a-synclein aggregation.",
                    "judgment": "Yes",
                    "reasoning": "The paper provides explicit statements about the disease's molecular basis and how the PINK1 gene/protein functions within it."
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The paper uses in vitro cell culture systems to investigate the effects of mutant PINK1 or PINK1 knock-down on mitochondrial function, proteasome function, and a-synclein aggregation.",
                    "judgment": "Yes",
                    "reasoning": "The use of in vitro cell culture systems is a standard technique in the field for studying Parkinson's disease pathogenesis."
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_steps": [
                        {
                            "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
                            "questions": [
                                {
                                    "question": "Were basic controls included for this assay? Specifically, were 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                    "answer": "Yes"
                                },
                                {
                                    "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                    "answer": "Not specified"
                                }
                            ]
                        },
                        {
                            "sub_step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                            "questions": []
                        },
                        {
                            "sub_step_name": "Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a)",
                            "questions": [
                                {
                                    "question": "Were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                    "answer": "Not specified"
                                }
                            ]
                        },
                        {
                            "sub_step_name": "Sub-step 4a: Statistical Analyses",
                            "questions": [
                                {
                                    "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                    "answer": "Not specified"
                                }
                            ]
                        },
                        {
                            "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
                            "questions": [
                                {
                                    "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                    "answer": "Not specified"
                                }
                            ]
                        },
                        {
                            "sub_step_name": "Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient)",
                            "questions": []
                        }
                    ]
                }
            ],
            "functional_evidence_strength": "Max PS3_supporting / Max BS3_supporting"
        }
    ]
}